143 related articles for article (PubMed ID: 11022712)
1. [Leuprorelin acetate depot].
Mashimo T
Nihon Rinsho; 2000 Jul; 58 Suppl():191-6. PubMed ID: 11022712
[No Abstract] [Full Text] [Related]
2. [Long-acting depot of LH-RH agonist].
Akaza H
Nihon Rinsho; 2000 Jul; 58 Suppl():309-11. PubMed ID: 11022737
[No Abstract] [Full Text] [Related]
3. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
4. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
5. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
6. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
7. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
[TBL] [Abstract][Full Text] [Related]
8. Injection systems for two luteinising hormone-releasing hormone agonists: a comparative assessment of administration times and nurses' perceptions.
Morgan G; Cooley C
Eur J Oncol Nurs; 2005 Dec; 9(4):334-40. PubMed ID: 16298160
[TBL] [Abstract][Full Text] [Related]
9. Leuprorelin acetate granulomas: case reports and review of the literature.
Yasukawa K; Sawamura D; Sugawara H; Kato N
Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
[TBL] [Abstract][Full Text] [Related]
10. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
[No Abstract] [Full Text] [Related]
11. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.
Sethi R; Sanfilippo N
Clin Interv Aging; 2009; 4():259-67. PubMed ID: 19554097
[TBL] [Abstract][Full Text] [Related]
12. Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.
Blumberg JM; Kwon EO; Cheetham TC; Niu F; Shapiro CE; Pacificar J; Loo RK; Williams SG; Chien GW
Urology; 2011 Feb; 77(2):412-6. PubMed ID: 21111460
[TBL] [Abstract][Full Text] [Related]
13. Leuprorelin acetate in prostate cancer: a European update.
Persad R
Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
[TBL] [Abstract][Full Text] [Related]
14. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
Lim CN; Salem AH
Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
[TBL] [Abstract][Full Text] [Related]
15. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
17. Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature.
Fujisaki A; Kondo Y; Goto K; Morita T
Int J Urol; 2012 Jan; 19(1):81-4. PubMed ID: 22050405
[TBL] [Abstract][Full Text] [Related]
18. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
19. Morphologic patterns of human endometrial epithelium in women with uterine myomata treated with leuprorelin acetate.
Palmara V; Triolo O; Benedetto V; Lo Re C; Sturlese E; Retto G; Santoro G
Gynecol Obstet Invest; 2010; 69(2):131-5. PubMed ID: 19996602
[TBL] [Abstract][Full Text] [Related]
20. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
